Three independent discounted-cash-flow-style models value Humacyte, Inc. Common Stock every trading day. 1 of 3 currently price HUMA above its market price.
| Free Cash Flow model | $-1.13 |
| Excess Profit model | $-6.07 |
| Residual Earnings model | $106,542.42 |
| Dividend Discount model | — |
| Piotroski F-Score | 2 / 9 |
| Return on invested capital | -105.9% |
| Net debt / EBITDA | — |
| Gross margin | -376.1% |
| Revenue CAGR | +27.0% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -53.5% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open HUMA in StockKitty